<DOC>
	<DOCNO>NCT02367313</DOCNO>
	<brief_summary>This Phase 2 protocol design compare two dose level Vapendavir versus placebo . The objective obtain safety efficacy data moderate severe asthmatic patient , age 18 75 year risk loss asthma control due presumptive Human Rhinovirus infection .</brief_summary>
	<brief_title>A Phase 2 Study Vapendavir Asthmatic Adults With Symptomatic Human Rhinovirus Infection</brief_title>
	<detailed_description>This multicenter trial conduct approximately 60 site among 6−8 northern hemisphere country North America Central Europe . Sufficient patient randomize order recruit 150 subject laboratory confirm human rhinovirus ( HRV ) infection . Depending HRV PCR positivity rate , expect randomization 250-480 subject require achieve number subject HRV infection . Appropriate asthma subject screen 180 day prior presentation study site symptom presume HRV infection potential study inclusion Study Day 1 . The study drug treatment period duration 7 day , begin Study Day 1 . Follow-up study visit clinic occur Study Days 3 , 5 , 7 , 14 , 21 , 28 telephonic final safety follow-up visit conduct Study Day 35 . Thus , depend duration screen period , subject 's duration participation estimate last approximately 37 day 215 day .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<criteria>1 . Moderate severe male female asthma subject age 18 75 year , ( inclusive ) 2 . Established clinical history Asthma least 1 year , history within last 14 month ( prior screening ) asthma exacerbation due presume viral respiratory infection , require asthma rescue medication treatment . 3 . The asthma subject currently take least mediumdose highdose ICS define fluticasone dosage least &gt; 264 µg daily may take asthma medication preparation . The asthma subject ' medication regimen must stable least 4 week screen . 4 . Subjects screen within last year , document variable airway obstruction indicate increase FEV1 ( &gt; 12 % ) short act bronchodilator , positive methacholine challenge , positive histamine challenge ( PC20 &lt; 8 mg/mL ) . 5 . Upon presentation clinic cold symptom , subject require randomized treat within 48 hour symptom onset qualified presumptive rhinovirus infection : 1. clinical exam presence follow Day 1 WURSS21 symptom severity 2 great : runny nose , sore throat , scratchy throat . 2. subject must also minimum total symptom score Day 1 WURSS21 20 point . 3. subject qualify presumptively infect HRV via exclusion subject significant fever exclusion subject test positive influenza via Rapid Antigen Test . 1 . Subjects present clinic current severe asthma exacerbation exclude randomization , well subject additional underlying respiratory medical condition asthma COPD , cystic fibrosis , chronic sinusitis , uncontrolled clinically significant disease would interfere assessment outcome subject safety . 2 . Female subject must pregnant breastfeeding . Females childbearing potential must willing utilize double barrier method contraception , define protocol , regardless hormonal contraception may concomitantly receive . 3 . Male subject must agree use method birth control define protocol . 4 . The use medication know moderately severely inhibit induce cytochrome ( CYP ) 3A4 2C19 enzyme , know sensitive substrate ( narrow therapeutic range ) CYPs restrict .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Symptomatic Human Rhinovirus Infection</keyword>
	<keyword>Moderate Severe Asthma</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Cold</keyword>
	<keyword>Aviragen Therapeutics , Inc .</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>